Can leptomeningeal metastasis cause vomiting and headache, and is hydrocephalus more likely than leptomeningeal metastasis to cause these symptoms?

Leptomeningeal Metastasis Can Cause Both Vomiting and Headache, But Hydrocephalus is Not More Likely—They Often Coexist

Yes, leptomeningeal metastasis (LM) directly causes both headache and vomiting, and these symptoms are among the most frequent manifestations at presentation. The question of whether hydrocephalus or LM is "more likely" to cause these symptoms is somewhat misleading, as hydrocephalus in this context is typically a complication of LM itself, not a separate competing diagnosis.

Clinical Presentation of Leptomeningeal Metastasis

Headache and nausea/vomiting are listed as the most frequent manifestations of LM at presentation 1. According to EANO-ESMO guidelines, these symptoms should alert clinicians to consider LM, particularly in patients with breast cancer, lung cancer, or melanoma 1.

The pathophysiology is multifactorial:

• Direct meningeal irritation: Tumor cells invading the leptomeninges cause inflammation and irritation of pain-sensitive structures 1
• Increased intracranial pressure: Many symptoms are "in part or largely related to increased intracranial pressure due to CSF circulation disturbances" 1
• CSF flow obstruction: This can occur at multiple levels including the base of the brain, spinal subarachnoid space, and cerebral convexities 1

The Relationship Between LM and Hydrocephalus

Hydrocephalus is a complication that occurs in 11%-17% of patients with LM 1, not a separate competing diagnosis. When present, hydrocephalus contributes significantly to the headache and vomiting symptoms through elevated intracranial pressure 1.

Prognostic Significance of Hydrocephalus

The presence of hydrocephalus at LM diagnosis is an independent negative prognostic factor:

• Absence of hydrocephalus at diagnosis is associated with improved survival (HR: 0.42,95% CI: 0.22-0.79, p=0.007) 2
• Baseline Evans index (a measure of ventricular size) below 0.27 correlates with longer survival: 5.3 months versus 1.3 months for those with EI ≥0.27 (HR 1.70, p=0.0099) 3

Clinical Management Algorithm

When Symptoms Are Present:

1. Immediate assessment: Perform detailed neurological examination looking specifically for multifocal signs including cranial nerve palsies, gait difficulties, and mental status changes 1

2. Imaging: Obtain cerebrospinal MRI with specific sequences (axial T1-weighted, axial FLAIR, axial diffusion, post-gadolinium 3D T1-weighted and 3D FLAIR for brain; post-gadolinium sagittal T1-weighted for spine) 1

3. Identify hydrocephalus: Look for communicating hydrocephalus on imaging, which occurs in 11%-17% of LM patients 1

Treatment Approach for Symptomatic Relief:

If hydrocephalus is present with severe headache and vomiting, CSF diversion should be strongly considered:

• Symptomatic improvement occurs in 67%-100% of patients 4
• Headache relief is achieved in 88% of patients undergoing shunt surgery 5
• Karnofsky Performance Status improves significantly (mean increase of 17.6 points, p<0.0001) 4
• Symptoms can be "rapidly alleviated by lowering intracranial pressure through CSF drainage" 1

CSF shunting options include:

• Ventriculoperitoneal shunt (VPS) 6, 5
• Lumboperitoneal shunt (LPS)—less invasive and simpler, particularly suitable for frail patients 7, 5

Important Caveats:

• CSF diversion does not improve overall survival (pooled HR 0.42,95% CI 0.09-1.94, p=0.27) 4, but it significantly improves quality of life and allows patients to receive further oncologic therapy 8
• Median survival after shunt placement is 2.43 months, but 79% of patients are discharged home or to rehabilitation facilities, and 56% receive additional systemic therapy post-shunt 8
• Complication rates range from 0%-21.1%, including infection (5%), symptomatic subdural collections (6.3%), and shunt revision (8%) 8, 4
• Peritoneal seeding from CSF diversion is rare (3.2% in one series) 6, 8

Key Clinical Pitfall

Do not dismiss headache and vomiting as simply "hydrocephalus" versus "LM"—they represent a continuum where LM causes both direct meningeal symptoms and secondary hydrocephalus. The presence of hydrocephalus indicates more advanced disease with worse prognosis 2, 3, but aggressive symptom management with CSF diversion can meaningfully improve quality of life even if survival is not extended 4.